Podcast Douglas W. Blayney, MD @BlayneyDouglas @StanfordMed @BeyondSpringInc #ASCO22 #OncoTwitter @oncoalert Phase 3...

1 year 25 Views

Douglas W. Blayney, MD, FASCO, Clinical researcher and breast oncologist, Professor of Medicine at Stanford University. In this audio, he speaks about the ASCO 2022 Abstract - Real-world effectiveness of prophylactic granulocyte colony-stimulating factor (G-CSF) early (week 1) and late (weeks 2-3) in the cycle for the prevention of febrile neutropenia (FN) among patients (pts) with breast cancer (BC) after high FN–risk chemotherapy (chemo).


The major goal of this study is to compare the percentage of patients with DSN =0 in patients treated with:

Docetaxel, doxorubicin, and cyclophosphamide (TAC) plus pegfilgrastim versus TAC + plinabulin/pegfilgrastim combo

Severe neutropenia is defined as an absolute neutrophil count (ANC) of 0.5109/L.

The chemotherapy in this study will consist of docetaxel, doxorubicin, and cyclophosphamide (TAC).